Suppr超能文献

非酒精性脂肪性肝病和/或代谢相关脂肪性肝病患者的临床特征差异及死亡结局。

Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.

机构信息

Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California.

Division of Gastroenterology and Hepatology, Palo Alto Veterans Affairs Health Care System, Palo Alto, California.

出版信息

Clin Gastroenterol Hepatol. 2021 Oct;19(10):2172-2181.e6. doi: 10.1016/j.cgh.2021.05.029. Epub 2021 May 23.

Abstract

BACKGROUND & AIMS: Metabolic dysfunction-associated fatty liver disease (MAFLD) establishes new criteria for diagnosing fatty liver disease independent of alcohol intake and concomitant viral hepatitis infection. However, the long-term outcomes of patients with MAFLD are sparse. We aimed to describe the characteristics and long-term survival of persons meeting criteria for nonalcoholic fatty liver disease (NAFLD) only (non-MAFLD NAFLD), for both NAFLD and MAFLD (NAFLD-MAFLD), and for MAFLD only (non-NAFLD MAFLD).

METHODS

Using data from the Third National Health and Nutrition Examination Survey (NHANES III) 1988-1994, 2997 participants with fatty liver identified via ultrasound were categorized into 3 distinct groups: non-MAFLD NAFLD, NAFLD-MAFLD, and non-NAFLD MAFLD.

RESULTS

Participants in the NAFLD-MAFLD and non-NAFLD MAFLD groups were older, had more metabolic traits and higher mean liver enzymes. Nearly 8% of participants in the non-NAFLD MAFLD group had advanced fibrosis (Fibrosis-4 index >2.67), while only 1.3% and 1.9% in the NAFLD-MAFLD and non-MAFLD NAFLD groups did, respectively (P < .0001). Non-NAFLD MAFLD participants had the highest cumulative incidence of all-cause mortality (26.2%) followed by those with NAFLD-MAFLD then non-MAFLD NAFLD participants (21.1% and 10.6%, respectively; P < .0001). Similar findings were observed for cardiovascular disease-related and other-cause (noncardiovascular disease, noncancer) mortality. Non-NAFLD MAFLD was independently associated with all-cause mortality compared with non-MAFLD NAFLD (adjusted hazard ratio, 2.4; 95% confidence interval, 1.2-4.6; P = .01).

CONCLUSIONS

MAFLD criteria identified a significant group of people with more comorbidities and worse prognosis compared with those with NAFLD only. These criteria should be considered in the general population to identify high-risk groups for early interventions.

摘要

背景与目的

代谢相关脂肪性肝病(MAFLD)建立了新的诊断标准,可独立于酒精摄入和伴发的病毒性肝炎感染来诊断脂肪肝疾病。然而,MAFLD 患者的长期预后数据较为缺乏。本研究旨在描述仅符合非酒精性脂肪性肝病(NAFLD)标准(非 MAFLD-NAFLD)、同时符合 MAFLD 和 NAFLD 标准(MAFLD-NAFLD)以及仅符合 MAFLD 标准(非 NAFLD-MAFLD)的人群的特征和长期生存情况。

方法

使用来自第三次全国健康和营养检查调查(NHANES III)1988-1994 年的数据,通过超声检查识别出的 2997 例脂肪肝患者被分为 3 个不同的组别:非 MAFLD-NAFLD、MAFLD-NAFLD 和非 NAFLD-MAFLD。

结果

MAFLD-NAFLD 和非 NAFLD-MAFLD 组的参与者年龄更大,具有更多的代谢特征和更高的平均肝酶水平。非 NAFLD-MAFLD 组中近 8%的患者存在晚期纤维化(Fibrosis-4 指数>2.67),而 MAFLD-NAFLD 组和非 MAFLD-NAFLD 组分别仅为 1.3%和 1.9%(P<0.0001)。非 NAFLD-MAFLD 患者的全因死亡率累积发生率最高(26.2%),其次是 MAFLD-NAFLD 组,然后是非 MAFLD-NAFLD 组(分别为 21.1%和 10.6%;P<0.0001)。心血管疾病相关死亡率和其他原因(非心血管疾病、非癌症)死亡率也有类似的发现。与非 MAFLD-NAFLD 相比,非 NAFLD-MAFLD 与全因死亡率独立相关(调整后的危险比,2.4;95%置信区间,1.2-4.6;P=0.01)。

结论

MAFLD 标准识别出了一组与仅符合 NAFLD 标准的人群相比,具有更多合并症和更差预后的人群。在普通人群中应考虑使用这些标准来识别有早期干预需求的高危人群。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验